FarmaKology-Mutations in SARS-CoV-2 Omicron variant promote cell binding

Jan 17, 2022

Today's Company

Vir Biotechnology

Vir Biotechnology brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

News

Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ (RTM™) technology platform, a unique antibody drug creation approach.

Hikma expands into Canada with acquisition of Teligent sterile injectable assets

Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs.

Australia regulator flags 'significant concerns' of price hike in COVID-19 antigen tests

Australia's competition regulator on Monday said it had "significant concerns" about reports of price gouging of COVID-19 rapid antigen tests and sought information from suppliers, retailers and pharmacy chains about rising costs. Australia is facing a shortage of at-home rapid antigen test kits after authorities urged asymptomatic close contacts to bypass government-funded testing hubs, where high volumes delayed results, and take their own tests.